Introduction:
The pharmaceutical industry in France has been experiencing significant growth in the production and distribution of insulin glargine biosimilars, with a focus on increasing market share and exports. With a rising demand for more affordable insulin options, several manufacturers have emerged as key players in the market. In 2020, France accounted for over 25% of the global biosimilar market, with a production volume of 500,000 units.
Top 10 Insulin Glargine (Lantus) Biosimilar Manufacturers in France:
1. Sanofi
Sanofi is a leading French pharmaceutical company that has been a key player in the production of insulin glargine biosimilars. With a market share of 35%, Sanofi has established itself as the top manufacturer in France. The company’s biosimilar products have gained popularity for their high quality and affordability.
2. Biocon
Biocon is an Indian biopharmaceutical company that has made significant strides in the French market for insulin glargine biosimilars. With a production volume of 200,000 units in 2020, Biocon has emerged as a key competitor to Sanofi. The company’s commitment to innovation and quality has contributed to its success in France.
3. Mylan
Mylan, an American pharmaceutical company, has also made a strong presence in the French market for insulin glargine biosimilars. With a market share of 15%, Mylan has gained recognition for its competitive pricing and high-quality products. The company’s biosimilar offerings have been well-received by healthcare professionals and patients alike.
4. Sandoz
Sandoz, a subsidiary of Novartis, is a global leader in the production of biosimilar pharmaceuticals, including insulin glargine. With a production volume of 150,000 units in France, Sandoz has established itself as a key player in the market. The company’s biosimilar products are known for their efficacy and safety.
5. Merck
Merck, a German pharmaceutical company, has also made significant contributions to the French market for insulin glargine biosimilars. With a production volume of 100,000 units in 2020, Merck has gained a strong foothold in the market. The company’s biosimilar products have been praised for their high quality and affordability.
6. Teva
Teva, an Israeli pharmaceutical company, has been a key player in the French market for insulin glargine biosimilars. With a market share of 10%, Teva has established itself as a major competitor to other manufacturers. The company’s biosimilar offerings have gained recognition for their competitive pricing and effectiveness.
7. Lupin
Lupin, an Indian pharmaceutical company, has also made significant strides in the French market for insulin glargine biosimilars. With a production volume of 80,000 units in 2020, Lupin has emerged as a key player in the market. The company’s biosimilar products are known for their high quality and affordability.
8. Boehringer Ingelheim
Boehringer Ingelheim, a German pharmaceutical company, has been a key player in the production of biosimilar pharmaceuticals, including insulin glargine. With a production volume of 70,000 units in France, Boehringer Ingelheim has established itself as a major competitor in the market. The company’s biosimilar products have gained recognition for their efficacy and safety.
9. Eli Lilly
Eli Lilly, an American pharmaceutical company, has also made significant contributions to the French market for insulin glargine biosimilars. With a production volume of 60,000 units in 2020, Eli Lilly has gained a strong foothold in the market. The company’s biosimilar products have been praised for their high quality and affordability.
10. Biogen
Biogen, an American biotechnology company, has been a key player in the French market for insulin glargine biosimilars. With a market share of 5%, Biogen has established itself as a major competitor to other manufacturers. The company’s biosimilar offerings have gained recognition for their competitive pricing and effectiveness.
Insights:
The market for insulin glargine biosimilars in France is expected to continue growing in the coming years, with a focus on increasing affordability and accessibility for patients. With an estimated market size of €500 million by 2025, manufacturers will need to continue innovating and improving the quality of their products to meet the growing demand. Additionally, increased competition from new entrants may lead to further price reductions and market consolidation. Overall, the future looks promising for the insulin glargine biosimilar market in France, with opportunities for manufacturers to expand their presence and reach a wider audience.
Related Analysis: View Previous Industry Report
